CXI Healthcare Technology Group Limited (KOSDAQ:900120)
1,040.00
+120.00 (13.04%)
At close: Aug 24, 2026
KOSDAQ:900120 Revenue
CXI Healthcare Technology Group had revenue of 7.52B KRW in the quarter ending March 31, 2026, a decrease of -27.51%. This brings the company's revenue in the last twelve months to 51.45B, down -20.11% year-over-year. In the fiscal year ending June 30, 2025, CXI Healthcare Technology Group had annual revenue of 57.64B, down -16.97%.
Revenue (ttm)
51.45B
Revenue Growth
-20.11%
P/S Ratio
0.34
Revenue / Employee
5.14B
Employees
10
Market Cap
17.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 57.64B | -11.78B | -16.97% |
| Jun 30, 2024 | 69.42B | -2.20B | -3.07% |
| Jun 30, 2023 | 71.62B | -29.76B | -29.35% |
| Jun 30, 2022 | 101.38B | -3.22B | -3.08% |
| Jun 30, 2021 | 104.59B | 41.19B | 64.96% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 94.89B |
| ChoA Pharmaceutical Co., LTD. | 61.16B |
| WooGene B&G | 56.49B |
| Seoul Pharma | 51.08B |
| Union Korea Pharm | 25.45B |
| Daesung Microbiological Labs. | 25.20B |
| BIFIDO | 14.63B |
| Pharmsville | 11.20B |